Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Nirmal Bhide"'
Publikováno v:
Neurochemistry International. 114:85-98
l -DOPA remains the primary treatment for Parkinson's disease (PD). Unfortunately, its therapeutic benefits are compromised by the development of abnormal involuntary movements (AIMs) known as l -DOPA-induced dyskinesia (LID). The norepinephrine (NE)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::844f4f31220f10422d23c87c4f580222
https://doi.org/10.1016/j.neuint.2018.01.010
https://doi.org/10.1016/j.neuint.2018.01.010
Autor:
Jessica A. George, Margaret A. Surrena, David Lindenbach, Christopher Bishop, Nirmal Bhide, Christopher J. Barnum
Publikováno v:
Journal of Neurochemistry. 134:222-232
Dopamine (DA) replacement therapy with L-DOPA continues to be the primary treatment of Parkinson's disease; however, long-term therapy is accompanied by L-DOPA-induced dyskinesias (LID). Several experimental and clinical studies have established that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe600e4e4a9f93da9d59f501fc49935e
https://doi.org/10.1111/jnc.13125
https://doi.org/10.1111/jnc.13125
Autor:
David Lindenbach, Nirmal Bhide, Adam A. Goldenberg, Stefanie Tignor, Christopher J. Barnum, Hannah Walters, Margaret A. Surrena, Christopher Bishop, Anna Klioueva
Publikováno v:
Pharmacology Biochemistry and Behavior. 100:607-615
While L-3,4-dihydroxyphenylalanine (L-DOPA) remains the standard treatment for Parkinson's disease (PD), long-term efficacy is often compromised by L-DOPA-induced dyskinesia (LID). Recent research suggests that targeting the noradrenergic (NE) system
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ed9afbc6821d650197b196717a06280
https://doi.org/10.1016/j.pbb.2011.09.009
https://doi.org/10.1016/j.pbb.2011.09.009
Publikováno v:
European Journal of Pharmacology. 644:67-72
The acute administration of MDMA has been shown to promote glycogenolysis and increase the extracellular concentration of glucose in the striatum. In the present study the role of serotonergic and/or noradrenergic mechanisms in the MDMA-induced incre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7fb7bf8ba69123c38f0596c0cfc429b
https://doi.org/10.1016/j.ejphar.2010.07.004
https://doi.org/10.1016/j.ejphar.2010.07.004
Publikováno v:
Brain Research. 1286:32-41
Repeated exposure to sub-lethal insults has been reported to result in neuroprotection against a subsequent deleterious insult. The purpose of this study was to evaluate whether repeated exposure (preconditioning) to a non-5-HT depleting dose of MDMA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a14f0f66ccd35368c2e58e585d25eac6
https://doi.org/10.1016/j.brainres.2009.06.042
https://doi.org/10.1016/j.brainres.2009.06.042
Autor:
Joy Hallmark, Melissa M. Conti, Noel Palumbo, Jessica A. George, Christopher Bishop, Corinne Y. Ostock, Nirmal Bhide
Long-term l-DOPA use for Parkinson's disease (PD) is frequently complicated by the emergence of a debilitating motor side effect known as l-DOPA-induced dyskinesia (LID). Accumulating evidence has implicated the norepinephrine (NE) system in the path
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8ebbc74275df9656aebf20dc0bfaa05
https://europepmc.org/articles/PMC4466080/
https://europepmc.org/articles/PMC4466080/
Recent studies have demonstrated that a preconditioning regimen (i.e., repeated low doses) of MDMA provides protection against the reductions in tissue concentrations of 5-HT and 5-HT transporter (SERT) density and/or expression produced by a subsequ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0502f5b209113e6c66140caa93ee1f58
https://europepmc.org/articles/PMC3578032/
https://europepmc.org/articles/PMC3578032/
Autor:
Nirmal Bhide, Margaret A. Surrena, S. Paul Berger, Christopher Bishop, Adam A. Goldenberg, David Lindenbach, Melanie A. Paquette
Publikováno v:
Psychopharmacology. 227(3)
l-DOPA continues to be the primary treatment for patients with Parkinson’s disease; however, the benefits of long-term treatment are often accompanied by debilitating side effects known as dyskinesias. In recent years, several 5-HT1A receptor agoni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf568840d6313d2de0cee6bdc809459f
https://pubmed.ncbi.nlm.nih.gov/23389756
https://pubmed.ncbi.nlm.nih.gov/23389756
Autor:
Christopher Bishop, Nirmal Bhide
Publikováno v:
Etiology and Pathophysiology of Parkinson's Disease
Parkinson's disease (PD) is a neurodegenerative disorder affecting millions worldwide and is one of the most common diseases affecting the aging population (Delau et al., 2006). Clinical hallmarks of PD feature severe motor deficits characterized by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36b371edcadaba56a5a814629ec3d1d7
https://doi.org/10.5772/21140
https://doi.org/10.5772/21140
Autor:
David Lindenbach, Nirmal Bhide, Karen L. Eskow Jaunarajs, Kristin B. Dupre, Christopher Bishop, Corinne Y. Ostock, Christopher J. Barnum
Chronic dopamine (DA) replacement therapy in Parkinson's disease (PD) leads to deleterious motor sequelae known as L-3,4,-dihydroxyphenylalanine (L-DOPA)-induced dysinesias (LID). No known therapeutic can eliminate LID, but preliminary evidence sugge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffa199efcb4bfafee0f45bded8e37d26
https://europepmc.org/articles/PMC3101009/
https://europepmc.org/articles/PMC3101009/